Comparative Study on Collagen-Binding Enzyme-Linked Immunosorbent Assay and Ristocetin Cofactor Activity Assays for Detection of Functional Activity of von Willebrand Factor

Peter L. Turecek; Jürgen Siekmann; Hans Peter Schwarz

doi:10.1055/s-2002-27817

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2002; 28(2): 149-160
DOI: 10.1055/s-2002-27817

Comparative Study on Collagen-Binding Enzyme-Linked Immunosorbent Assay and Ristocetin Cofactor Activity Assays for Detection of Functional Activity of von Willebrand Factor

Peter L. Turecek, Jürgen Siekmann, Hans Peter Schwarz

Baxter Bioscience, Vienna, Austria

Abstract

ABSTRACT

For more than two decades, the ristocetin cofactor (RCo) assay, which measures the von Willebrand factor (vWF)-mediated agglutination of platelets in the presence of the antibiotic ristocetin, has been the most common method for measuring the functional activity of vWF. There is, however, general agreement among clinical analysts that this method has major practical disadvantages in performance and reproducibility. Today, collagen-binding assays (CBA) based on the enzyme-linked immunosorbent assay (ELISA) technique that measure the interaction of vWF and collagen are an alternative analytic procedure based on a more physiological function than that of the RCo procedure. We used both assay systems in a comparative study to assess the functional activity of vWF in plasma as well as in therapeutic preparations. We measured RCo activities of plasma from healthy donors and patients with different types of von Willebrand disease (vWD) and of vWF as a drug substance in factor (F) VIII/vWF concentrates using both the aggregometric and the macroscopic methods. In addition, we measured collagen-binding activity (vWF:CB) using a recently developed commercially available CBA system. To investigate the relation between the structure and the functional activity of vWF, we isolated vWF species with different numbers of multimers from FVIII/vWF concentrates by affinity chromatography on immobilized heparin. The vWF:RCo and vWF:CB of the different fractions were measured, and the multimeric structure of vWF was analyzed by sodium dodecyl sulfate (SDS) agarose gel electrophoresis. (vWF:CB and vWF:RCo are part of the nomenclature proposed by the International Society on Thrombosis and Hemostasis Scientific and Standardization Committee [ISTH SSC] subcommittee on von Willebrand factor, in Maastricht, Germany, June 16, 2000.) Measurement of functional vWF activity by CBA can be carried out with substantially higher interassay reproducibility than can measurement of RCo. Both assay systems can be used for diagnosis and subtyping of vWD, but CBA is more sensitive than either of the two RCo methods. The analysis of vWF multimers in the different fractions obtained by affinity chromatography on heparin Sepharose showed that the activity measured both with RCo assay and CBA correlated with the degree of multimerization. Our results suggest that measurement of the functional activity of vWF by the RCo procedure can be replaced by the more reliable CBA, reflecting the physiological hemostatic activity of vWF. The CBA method appears not only to be more sensitive and easier to carry out than the RCo method is but also to have a higher reproducibility and allow better standardization.

KEYWORDS

von Willebrand factor - vWF - ristocetin cofactor activity - collagen-binding activity - FVIII/vWF concentrates - von Willebrand disease - heparin affinity chromatography

Full Text

References

REFERENCES

1 Ruggeri Z M. Structure and function of von Willebrand factor. Thromb Haemost . 1999; 82 576-584
2 Sadler J E. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem . 1998; 67 395-424
3 Girma J P, Ribba A S, Meyer D. Structure-function relationship of the A1 domain of von Willebrand factor. Thromb Haemost . 1995; 74 156-160
4 Fowler W E, Fretto L J, Hamilton K K, Erickson H P, McKee P A. Substructure of human von Willebrand factor. J Clin Invest . 1985; 76 1491-1500
5 Furlan M, Robles R, Affolter D. Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers. Proc Natl Acad Sci USA . 1993; 90 7503-7507
6 Fischer B E, Thomas K B, Schlokat U, Dorner F. Triplet structure of human von Willebrand factor. Biochem J . 1998; 331(part 2) 483-488
7 Sobel M, Soler D F, Kermode J C, Harris R B. Localization of a heparin binding domain peptide of human von Willebrand factor. J Biol Chem . 1992; 267 8857-8862
8 Kroner P A, Frey A B. Analysis of the structure and function of the von Willebrand factor A1 domain using targeted deletions and alanine scanning mutagenesis. Biochemistry . 1996; 35 13460-13468
9 DeLuca M, Facey D A, Favaloro E J. Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation. Blood . 2000; 95 164-172
10 Sadler J E, Matsushita T, Dong Z, Tuley E A, Westfield L A. Molecular mechanism and classification of von Willebrand disease. Thromb Haemost . 1995; 74 161-166
11 Weiss H J, Hoyer L W, Rickles F R, Varma A, Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. J Clin Invest . 1973; 52 2708-2716
12 MacFarlane D E, Stibbe J, Kirby E P. A method for assaying von Willebrand factor (ristocetin cofactor). Thrombosis et Diathesis Haemorrhagica . 1975; 34 306-308
13 Vanhoorelbeke K, Cauwenberghs N, Vauterin S. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost . 2000; 83 107-113
14 Brown J E, Bosak J O. An ELISA test for the binding of von Willebrand factor antigen to collagen. Thromb Res . 1986; 43 303-311
15 Favaloro E J, Grispo L, Exner T, Koutts J. Development of a single collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II, von Willebrand's disease. Blood Coagul Fibrinolysis . 1991; 2 285-291
16 Siekmann J, Turecek P L, Schwarz H P. The determination of von Willebrand factor activity by collagen binding assay. Haemophilia . 1998; 4(Suppl 3) 15-24
17 Fehlner J R, Hutchinson R EJ, Tarbell D S, Schenck J R. Structure of ristocetin A. Proc Natl Acad Sci USA . 1972; 69 2420-2421
18 Williams D H, Rajajanda V, Kalman J R. On the structure and mode of action of the antibiotic ristocetin A. J Chem Soc Perkin I . 1979; 3 787-792
19 Waltho J P, Williams D H. Aspects of molecular recognition: solvent exclusion and dimerization of the antibiotic ristocetin when bound to a model bacterial cell-wall precursor. J Am Chem Soc . 1989; 111 2475-2480
20 Bardsley B, Williams D H, Baglin T P. Cleavage of rhamnose from ristocetin A removes its ability to induce platelet aggregation. Blood Coagul Fibrinolysis . 1998; 9 241-244
21 Perkins H R, Nieto M. The chemical basis for the action of the vancomycin group of antibiotics. Ann NY Acad Sci . 1974; 235 348-363
22 Gangarosa E J, Johnson T R, Ramos H S. Ristocetin-induced thrombocytopenia; site and mechanism of action. Arch Intern Med . 1960; 105 83-89
23 Howard M A, Firkin B G. Ristocetin-a new tool in the investigation of platelet aggregation. Thrombosis et Diathesis Haemorrhagica . 1971; 26 362-369
24 Howard M A, Sawers R J, Firkin B G. Ristocetin: a means of differentiating von Willebrand's disease into two groups. Blood . 1973; 41 687-690
25 Brinkhous K M, Read M S. Fixation platelets and platelet agglutination aggregation tests. Methods Enzymol . 1989 (part A); 169 149-163
26 Puri S, Gresham C, Kao K J. A simple quantitative assay for ristocetin cofactor activity using microtiter plate and ELISA plate reader. Thromb Res . 1994; 74 285-291
27 Engelhardt W, Patzke J, Pelzer H. Von Willebrand ristocetin cofactor: fast and precise determination on coagulation analyzers. Ann Hematol (Abst) . 1999; 78(Suppl I) A74
28 Jenkins C SP, Meyer D, Dreyfus M D, Larrieu M J. Willebrand and ristocetin. I. Mechanism of ristocetin-induced platelet aggregation. Br J Haematol . 1974; 28 561-578
29 Coller B S, Gralnick H R. Studies on the mechanism of ristocetin-induced platelet agglutination. J Clin Invest . 1977; 60 302-312
30 Scott J P, Montgomery R R, Retzinger G S. Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor-dependent agglutination of platelets. J Biol Chem . 1991; 266 8149-8155
31 Matsushita T, Sadler J E. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. J Biol Chem . 1995; 270 13406-13414
32 Coller B S. von Willebrand disease. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis, Basic Principles and Clinical Practice, 2nd ed Philadelphia: Lippincott 1987: 60-96
33 Azuma H, Sugimoto M, Ruggeri Z, Ware J. A role for von Willebrand factor proline residues 702- 704 in ristocetin mediated binding to platelet glycoprotein Ib. Thromb Haemost . 1993; 69 192-196
34 Hoylaerts M F, Nuyts K, Peerlinck K, Deckmyn H, Vermylen J. Promotion of binding of von Willebrand factor to platelet glycoprotein Ib by dimers of ristocetin. Biochem J . 1995; 306(part 2) 453-463
35 Ewenstein B M. von Willebrand's disease. Annu Rev Med . 1997; 48 525-542
36 Favaloro E J, Smith J, Petinos P, Hertzberg M, Koutts J. Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficiency by means of a multi-laboratory survey. Thromb Haemost . 1999; 82 1276-1282
37 Barrowcliffe T W, Kemball-Cook G, Morris G. Factor VIII-related activities in therapeutic concentrates. J Lab Clin Med . 1981; 97 429-438
38 Chang P, Aronson D L. Plasma derived von Willebrand factor preparations: collagen binding and ristocetin cofactor activities. Thromb Haemost . 1997; 78 930-933
39 Gilchrist M, Stewart M W, Etches W S, Gordon P A. Rapid diagnosis of von Willebrand's disease using ELISA technology. Thromb Res . 1990; 57 659-664
40 Thomas K B, Sutor A H, Zieger B. A simple test for the determination of the von Willebrand factor function: the collagen binding activity. Hämostaseologie . 1994; 14 133-139
41 Favaloro E J. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrand's disease (vWD), and discrimination of vWD subtypes, depends on collagen source. Thromb Haemost . 2000; 83 127-135
42 Fitzsimmons C M, Cockburn C G, Hornsey V, Prowse C V, Barnes M J. The interaction of von Willebrand factor (vWF) with collagen: Investigation of vWF-binding sites in the collagen molecule. Thromb Haemost . 1988; 59 186-192
43 Pareti F, Fujimura Y, Dent J. Isolation and characterization of a collagen binding domain in human von Willebrand factor. J Biol Chem . 1986; 261 15310-15315
44 Roth G J, Titani K, Hoyer L W, Hickey M J. Localization of binding sites within human von Willebrand factor for monomeric type III collagen. Biochemistry . 1986; 25 8357-8361
45 Miller E J, Gay S. Collagen: An overview and update. Methods Enzymol . 1987; 144 3-41
46 Furuto D K, Miller E J. Isolation and characterization of collagens and procollagens. Methods Enzymol . 1987; 144 41-61
47 Favaloro E J. Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects. Am J Clin Pathol . 2000; 114 608-618
48 Hillery C A, Manusco D J, Sadler J E. Type 2M von Willebrand disease: F6606I and I662F mutations in the glycoprotein binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets. Blood . 1998; 91 1572-1581
49 Ramasamy I, Farrugia A, Tran E, Anastasius V, Charnock A. Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay. Biologicals . 1998; 26 155-166
50 Human coagulation factor VIII, freeze-dried. In: Monography 1998;0275 European Pharmacopoeia, 3rd ed. 1998 (Suppl): 336-337
51 Ingerslev J. A sensitive ELISA for von Willebrand factor (vWF:Ag). Scand J Clin Lab Invest . 1987; 47 143-149
52 Murdock P J, Woodhams B J, Matthews K B, Pasi K J, Goodall A H. Von Willebrand factor activity detected in a monoclonal antibody-based ELISA: An alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost . 1997; 78 1272-1277
53 Chand S, McCraw A, Hutton R, Tuddenham E GD, Goodall A H. A two-site, monoclonal antibody-based immunoassay for von Willebrand factor-demonstration that vWF function resides in a conformational epitope. Thromb Haemost . 1986; 555 318-324
54 Preston F E. Assays for von Willebrand factor functional activity: A UK NEQAS survey. Thromb Haemost (Letter) . 1998; 80 863
55 Kessels H, Beguin S, Wagenvoord R, Hemker H C. A method for measuring activated factor VIII in plasma. Thromb Haemost . 1991; 66 430-434
56 Evans R J, Austen D EG. Assay of ristocetin co-factor using fixed platelets and a platelet counting technique. Br J Haematol . 1977; 37 289-294
57 Ruggeri Z M, Zimmerman T S. The complex multimeric composition of factor VIII/von Willebrand factor. Blood . 1981; 57 1140-1143
58 Turecek P L, Gritsch H, Pichler L. In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. Blood . 1997; 90 3555-3567
59 Aihara M, Sawada Y, Ueno K. Visualization of von Willebrand factor multimers by immunoenzymatic stain using avidin-biotin peroxidase complex. Thromb Haemost . 1986; 55 263-267
60 Siekmann J, Turecek P L, Schwarz H P. The hemostatic potency of von Willebrand factor in FVIII/vWF concentrates is reflected by affinity to immobilized heparin. Ann Hematol (Abst) . 1999; 78(Suppl I) A61
61 Wright R D, Krauss J S. A comparison of two macroscopic platelet agglutination assays for von Willebrand factor. Ann Clin Lab Sci . 1990; 20 73-78
62 Favaloro E J, Koutts J. Laboratory assays for von Willebrand factor: relative contribution to the diagnosis of von Willebrand's disease. Pathology . 1997; 29 385-391
63 De Romeuf C, Mazurier C. Heparin binding assay of von Willebrand factor (vWF) in plasma milieu-evidence of the importance of the multimerization degree of vWF. Thromb Haemost . 1993; 69 436-440
64 Fischer B E, Kramer G, Mitterer A. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII. Thromb Res . 1996; 84 55-66
65 Favaloro E J. Laboratory assessment as a critical component of the appropriate diagnosis and subclassification of von Willebrand's disease. Blood Rev . 1999; 13 185-204
66 Dean J A, Blanchette V S, Carcao M D. Von Willebrand disease in a pediatric-based population: Comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay. Thromb Haemost . 2000; 84 401-409
67 Rodheghiero F, Castaman G, Meyer D, Mannucci P M. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease. Vox Sang . 1992; 62 193-199
68 Menache D, Aronson D L. New treatments of von Willebrand disease: Plasma-derived von Willebrand factor concentrates. Thromb Haemost . 1997; 78 566-570
69 Auerswald G, Eberspächer B, Kreuz W. Successful treatment of patients with von Willebrand disease using a high purity double virus inactivated FVIII/vWF concentrate (IMMUNATE). Ann Hematol (Abst) . 2000; 79(Suppl I) A129